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Abstract     
We have identified a 101-amino-acid polypeptide derived from the sequence surrounding the IIA binding 
site of human albumin. The polypeptide contains residues that make contact with ligands as warfarin in 
the parent protein, and eight cysteine residues to form disulfide bridges, which stabilize the polypeptide 
structure. Seventy-four amino acids are located in six α-helical regions, with the remaining amino acids 
forming six connecting coil/loop regions. Codon usage optimization was used to express a GST fusion 
protein in E. coli in yields as high as 4 mg/l. This fusion protein retains its structural integrity and aldolase 
activity, the ability to direct the stereochemical outcome of a diketone reduction, and its binding capacity 
to warfarin and efavirenz. Notably, this newly cloned polypeptide represents a valuable starting point for 
the construction of libraries of binders and catalysts with improved proficiency. 
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Introduction 
 
In recent years, a number of different binding proteins have been proposed as alternatives to conventional 
antibody-based technologies. Affibodies1, anticalins2, knottins3 and neocarzinostatin-based4 peptide 
scaffolds are successful examples of such protein-protein or protein-peptide recognition systems5-7. 
However, the recognition of small molecules by peptides and proteins is more demanding. The engineering 
of novel protein scaffolds for binding small molecules has several drawbacks common also to competing 
antibody technologies. Both recombinant anti-hapten antibodies selected from in vitro display 
technologies and artificial protein receptors have, in general, a moderate affinity for small cognate 
molecules with Kd values in the micromolar range, comparable to those of the primary IgM immune 
response in animals. Obtaining higher-affinity antibodies or artificial receptors against haptens is still a 
challenge. Multiple “affinity maturation” approaches have been attempted8. As a general strategy, large, 
full-length gene libraries or, alternatively, focused optimized scaffolds can be constructed. In both cases, 
specific selection protocols must be devised, using modified haptens to optimize presentation to  the 
immune system or to synthetic libraries. Usually, small haptens are chemically modified at one functional 
group to introduce a reactive linker suitable for conjugation to a carrier protein or immobilization on a 
solid surface, often via biotinylation. This modification reduces the number of available interactions and 
constrains the orientation of the small ligand with respect to potential receptors. Furthermore, the linker 
and/or the carrier system can elicit a high level of cross reactivity  lowering the affinity for the free, 
unmodified hapten. A detailed example has been reported involving a testosterone-binding peptide 
derived from neocarzinostatin9. 
Peptide scaffolds, intermediate between large enzymes and small organocatalysts, have also been 
proposed as tailor-made catalysts for organic reactions10. In most cases, however,  successful catalysts are 
synthetic oligopeptides with notably short sequences of amino acids that only play an ancillary role to the 
main organocatalytic residue side chain (often acting by covalent catalysis) without forming a site for 
selective substrate recognition10. Tanaka and Barbas used phage display to obtain libraries of more 
structured peptides exhibiting aldolase activity 11,12. However, a general strategy for developing libraries 
of structured catalytic peptides that can control regio- and stereoselectivity in a wider variety of 
reactions has not yet been defined.  
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Being interested in the development of artificial peptides  that can efficiently combine  binding and 
catalysis, we reasoned that a convenient starting point would be a “wild-type” sequence that is capable of 
both recognizing a broad spectrum of small molecules with micromolar affinity and catalyzing a wide 
range of reactions with acceptable proficiency. This polypeptide should ideally present structural features 
that allow facile detection of binding to the free ligand, avoiding the use of modified targets in the 
selection  step. Such a peptide could be regarded as an “artificial IgM,” and the possible development of a 
library of binders by random or rational mutation strategies could mimic the "in vivo" antibody affinity 
maturation process in a single step. Serum albumin is a promising candidate due to its ability to bind a 
variety of small molecules with micromolar affinity13, and to control the outcome of certain chemical 
reactions. Broad binding activity and chemical reactivity are associated with the binding site located in 
the albumin IIA subdomain14, also known as Sudlow site I. A lysine residue is present in this binding site in 
both human and bovine serum albumin (K199 and K222 in HSA and BSA, respectively). In addition to being 
a site for covalent interactions with drugs such as aspirin and benzylpenicillin15, this basic lysine residue, 
which is surrounded by a hydrophobic environment, is responsible for the ability of albumin to behave as 
an enzyme-like catalyst in reactions such as β-eliminations16, the decomposition of Meisenheimer 
adducts17, and the Kemp elimination18,19. We have recently reported on albumin’s ability to direct the 
stereoselective reduction of diketones and catalyze the aldol reaction20-22. Furthermore, a tryptophan 
residue (W214) located at the bottom of the main hydrophobic subsite can be exploited as a useful 
internal fluorescent sensor for binding of this site to different ligands23,24. In addition, this residue allows 
the selection of binders in rapid screening protocols that do not require labeling or immobilization of the 
target ligand. In this report we describe the selection, cloning and characterization of a 101-amino-acid 
polypeptide derived from the sequence of the IIA binding site of human albumin that retains the ability of 
native albumin to bind typical ligands, such as warfarin and efavirenz, and to catalyze or control chemical 
reactions such as the aldol reaction and  the reduction of diketones. These results open the way to the use 
of this peptide as the base sequence for building libraries of stable artificial receptors and catalysts that 
can be easily selected for sensing and synthetic applications.   
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Results 
Identification, cloning and production of the GST-HSA100 polypeptide 
Based on structural and functional analyses, we have identified a peptide corresponding to a 101-residue 
stretch of the human serum albumin sequence (A194 to E294) named HSA100 (Fig. 1a). This fragment 
corresponded to approximately half of albumin’s subdomain IIa, containing Sudlow site I. This binding site 
is formed by a continuous sequence of amino acids with no contribution from residues from other 
subdomains. The HSA100 sequence included all the residues that contact typical albumin ligands, such as 
warfarin25, as well as all eight cysteine residues that are involved in the formation of the four disulfide 
bridges (C200-C246, C254-C252, C265-C279, C278-289), which probably stabilize the polypeptide 
structure. Seventy-four amino acids were located in six α-helical regions (α1, Q196-F206; α2, R209-R222; 
α3, A229-H247; α4, L250-S270; α5, L284-G292; α6, L284-G292), and the remaining residues were located in 
six connecting coil/loop regions. A molecular dynamics simulation  was performed at room temperature 
using the Gromacs package and demonstrated that HSA100 was conformationally stable for over 1000 ns 
simulation. However, significant unfolding occurred upon the exclusion of C200 or C289 from the designed 
peptide.  
To simplify production of the HSA100 fragment we decided to clone and express its coding sequence in E. 
coli. A preliminary evaluation of protein production was performed by fusing the HSA fragment to either a 
carrier maltose-binding protein (MBP) or different tag sequences (HIS6 and strep tags). Even though 
HSA100 was expressed, purified, and active, the protein yield was extremely poor (data not shown). To 
improve the yield, we used the following approach: the HSA100 DNA sequence was modified using a codon 
usage optimization strategy for E. coli expression; the fragment was cloned as a fusion protein with a 
glutathione S-transferase (GST) carrier (Fig. 1b), generating the GST-HSA100 fusion. After careful 
optimization of cell culture conditions, we managed to produce 15-20 mg/l of GST-HSA100 fusion protein 
and obtain up to 4 mg/l of soluble protein. The soluble fraction was purified by affinity chromatography 
using a GSH resin, resulting in highly pure, stable, full-length protein (Fig. 1c). 
 
Structural characterization of GST-HSA100 
LC-MS/MS and peptide sequencing analyses were performed to confirm the identity of GST-HSA100. 
Purified GST-HSA100 was trypsin-digested, and the resulting peptides were separated by RP-HPLC. The 
identities of the peptides were confirmed by comparison of theoretical and experimental m/z values of 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
89
4.
1 
: P
os
te
d 
17
 F
eb
 2
01
2
6 
 
full-length peptides (MS) and collision-induced dissociation (CID) fragments (MS/MS). The tryptic peptide 
map referring to the GST-HSA100 sequence is shown in Figure 1d, and the mass spectrometry data are 
summarized in supplementary Table 1. 
The circular dichroism spectra of the fusion protein in the near- and far-UV regions (Figure 2) were 
recorded at neutral pH and temperatures ranging from 25 to 75°C. The far-UV spectrum (Fig. 2a) was 
deconvoluted using the convex constraint algorithm26 to reveal a protein composition of 50% α-helix, 30% 
coil, 16% turn and <5% β-sheet. Thermal denaturation occurred above 60°C, but at 75°C the conserved 
amount of α-helix was still over 40%, with no clear trend towards complete unfolding (Fig. 2a). The 
presence of disulfide bonds was probed by near-UV CD spectroscopy (Fig. 2b). Several peaks were 
identified in the fine structure: the shoulder at 267 nm and minima at 276, 284 and 293 nm resemble a set 
of peaks attributed to the presence of disulfide bridges in the chiral environment of domain II of HSA27. 
 
Small molecule binding activity of GST-HSA100 
(±)-Warfarin and efavirenz (Figure 3a) were chosen as probes to test if the binding capacity of GST-HSA100 
was maintained. Warfarin is perhaps the most typical ligand for the subdomain IIa site, and the structure 
of the HSA complexes formed with both its enantiomers, which have similar affinity, have been fully 
described25. Efavirenz, an inhibitor of HIV reverse transcriptase, is a widely used drug in AIDS therapy and 
has led to increased interest in the therapeutic drug monitoring of antiretroviral drugs. Efavirenz, as many 
drugs, binds to HSA and interacts with the subdomain II site28. The interactions of the two ligands with the 
construct were first studied by fluorescence quenching experiments monitoring tryptophan emission. The 
emission spectrum of apo-GST-HSA100 is shown in Figure 3b (spectrum 1) as a synchronous scan at Δ = 60 
nm and shows an overall maximum at 281 nm excitation (i.e., 341 nm emission), while the emission 
maximum of native HSA is at 340 nm27. Conversely, it is well known that the four GST tryptophan residues 
have poor emission in native GST with a maximum at 335 nm as they are buried in a hydrophobic 
environment29. 
Quenching of GST-HSA100 fluorescence (1 μM in phosphate buffer, pH 7.4) was observed in the presence 
of both warfarin and efavirenz. The effect of efavirenz on the synchronous emission spectrum is shown in 
Fig. 3b, and similar results were obtained with warfarin (supplementary Figure 1). Quenching occurred 
and was accompanied by a blueshift of the excitation maximum from 281 to 278 nm. The highest 
quenching was obtained at 200 μM efavirenz, which is close to its solubility limit. In the difference 
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spectrum between unquenched and fully quenched GST-HSA100 emission, there is a shoulder 
corresponding to an emission maximum at 330 nm. The blueshift from 341 nm upon titration with 
efavirenz is consistent with a change of the polarity of the environment surrounding the emitter Trp 
residue, resulting from  replacement of the solvent in the active site by the less polar ligand. The buried, 
inaccessible, tryptophan residues in GST are likely to significantly contribute to the residual unquenched 
emission observed at 200 μM efavirenz  (Fig. 3b). The titration of fluorescence emission as a function of 
ligand concentration for HSA, GST-HSA100 and GST is reported in Figure 3c.  Both ligands had a similar  
quenching effect on HSA and GST-HSA100 , whereas the effect on GST fluorescence was negligible (Fig. 
3c). To determine whether the observed quenching was due to binding or collisional phenomena a Stern-
Volmer analysis of the quenching data was performed in the 4300–24500 l mol-1 range (Table 1). Assuming 
a 5-ns decay time for tryptophan fluorescence, the apparent bimolecular quenching constants derived 
from the Stern-Volmer constants were as high as 8 x 1011 – 4.9 x 1012 l mol-1s-1 (Table 1) and 2-3 orders of 
magnitude higher than the limit for diffusion–limited collisional quenching. The latter can thus be 
excluded in favour of  static quenching originating from the association of the fluorophore and quenchers 
in a bimolecular complex23,30. The ligand–protein dissociation constants were evaluated by a Hill analysis 
of the fluorescence data (Table 1). The KD values obtained for HSA and GST-HSA100  were similar and 
close to the literature values of 3.7–3.5 μM and 110 μM for warfarin31,32 and efavirenz binding to native 
HSA28, respectively. 
The binding of efavirenz to GST-HSA100 was also confirmed by a surface plasmon resonance experiment 
carried out on a Biacore instrument (Supplementary Fig. 2). Efavirenz was modified at position 1 of the 
benzoxazin-2-one system to obtain derivative 2b (Figure 3a) and this amine  was  immobilized on a 
carboxymethylated dextran matrix attached to the gold chip. The affinity measured from the SPR data 
was comparable to that obtained by fluorimetry (Table 1). 
 
Chemical reactivity control: diketone reduction 
1,3-Diols are naturally occurring compounds and important synthetic intermediates. Their preparation in 
diastereomerically pure form is a frequent target in organic synthesis, and has been achieved through 
several approaches, including biomimetic and organocatalytic methods. We found that anti 1,3-diol 4 can 
be obtained, with a diastereoisomeric excess of up to 96%, by the stereoselective reduction of diketone 3 
(Figure 4a) with sodium borohydride in aqueous acetonitrile in the presence of stoichiometric amounts of 
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bovine or human albumin  (Table 2)11. The same reaction, without albumin, is not stereoselective, yielding 
a 1:1 mixture of syn and anti diols 4. We carried out  the reduction of diketone 3 in the presence of GST-
HSA100 and we found that the level of stereoselectivity was comparable to that obtained with  native HSA 
(Table 2). Complete conversion of the substrate to anti-diol 4 takes place without loss of selectivity  and 
the anti diol can be easily recovered from the aqueous medium by simple extraction after denaturing the 
peptide with ethanol. 
 
Chemical reactivity control: aldolase activity 
The aldol reaction is one of the most important synthetic tools for the stereoselective formation of 
carbon-carbon bonds. This reaction is extremely useful when proficient catalytic and control systems are 
employed. Catalytic versions of this reactions have been proposed using metal catalysys, organocatalysis, 
and bio- and biomimetic catalysis.ref We have recently found that HSA and BSA catalyze the aldol addition 
of acetone to aldehyde 5 (Figure 4b) and other aromatic aldehydes  with an enzyme-like mechanism. The 
catalyzed process is three orders of magnitude faster than the uncatalyzed reaction, with Michaelis–
Menten constants in the millimolar range21. 
 GST-HSA100 behaved similarly to its parent protein (Fig. 5, Table 2) accelerating the reaction by over 
1100-fold. The construct exhibited multiple turnover, allowing more than 100 catalytic cycles and full 
conversion of a 100-fold excess of aldehyde 5 to aldol 6. 
 
Discussion 
HSA100 is the shortest functional peptide that has ever been derived from the sequence of HSA and, to 
the best of our knowledge, the first albumin fragment successfully expressed in E. coli.  
In the past decade, several larger fragments have been described. To define the structural elements 
required for the formation of the warfarin binding site, Rüker and colleagues prepared five fragments, 
including domains I, II, I-II, I-IIa and Ib-II27,33,34. 
Similar work was  completed by the East group on fragments corresponding to domains I-II and II-III 32. 
More recently, a recombinant protein corresponding to domain I-II was designed by Fasano35 to study the 
allosteric linkage between the warfarin and heme binding sites in the protein. Three recombinant full 
domains of HSA have also been prepared as potential drug delivery tools36.  All the described fragments, 
including native HSA, have been obtained as secreted proteins by expression in Pichia pastoris.  
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Using a combined strategy of optimizing DNA sequences and growth conditions, we were able to express 
and purify soluble, full-length GST-HSA100 protein in E. coli. Mass spectrometry in combination with SDS-
PAGE and anti-FLAG immunoblotting unambiguously demonstrated the correct production of a full-length 
recombinant soluble GST-HSA100 fusion construct (Fig. 1c, Supplementary Table 1).  
Our CD spectra support the correct folding of the GST-HSA100 protein. The secondary structure 
composition inferred from the CD data is as expected for GST-HSA100, containing the five helix and six 
coil/loop region of the GST-HSA100 domain and two GST domains with a βαβαββα folding topology along 
the first 84 residues followed by an extended α-helical domain of 132 amino acids at the C-terminus29. The 
thermal stability of the GST-HSA100 protein is also comparable to those of HSA and GST 37,38, and the 
formation of disulfide bridges is again consistent with a correct folding process. Four disulfide bridges 
should be present in the GST-HSA100 region of the construct, although none of the four cysteine residues 
in GST is believed to be involved in disulfide bond formation, even in the predominant homodimer that 
forms at micromolar concentrations29,39,40.  
Binding activity is conserved in the GST-HSA100 fragment, and the measured affinities fit well with the 
hosting capacities of the native protein. The conservation of the binding capacity is consistent with the 
correct organization of GST-HSA100, thereby enabling the correct formation of the binding site. Based on 
the fluorescence data, the affinity for free efavirenz in solution is similar to that measured on 
immobilized efavirenz by the SPR sensor. Efavirenz was immobilized to the sensor surface via its 
heterocyclic nitrogen, leaving the interaction with the protein and the aromatic/cyclopropyl moieties of 
the molecule exposed. This is consistent with the shape of the IIa binding site, which contains two 
hydrophobic subsites that host similar aromatic and hydrophobic groups. To design rapid screening 
methodology for binding by GST-HSA100, we performed the fluorescence-quenching titration in a 384-
microwell plate format using a fluorimetric plate reader equipped with 280±15 nm excitation and 350±15 
nm emission filters to detect tryptophan fluorescence. Due to the lower sensitivity of this method, 
microwell screening required a higher concentration of GST-HSA100 to provide a detectable fluorescence 
signal. However, the results are comparable with fluorimetric titrations in the spectrofluorimeter, 
enabling a considerably higher throughput and requiring less than a quarter of the volume (Supplementary 
Figure 3). This creates the possibility of screening libraries of mutated GST-HSA100 for improved binders. 
The control of diketone reduction (Fig. 4, Table 2) was again consistent with the high degree of structural 
conservation in GST-HSA100. This reaction requires the recognition of the 1,3-diketone in its enol form, 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
89
4.
1 
: P
os
te
d 
17
 F
eb
 2
01
2
10 
 
stabilization by ionizable residues H242 and K199 (native protein numbering) in their neutral and 
protonated forms, respectively, and the correct shape of the binding site around the enolized diketone to 
control the diastereoselectivity of the products. The initial chemoselectivity occurs in the reduction of the 
first (aliphatic) carbonyl, which is exposed to the solvent in the albumin-diketone complex, while the 
aromatic carbonyl is buried inside the albumin binding site. Subsequent diastereoselectivity occurs in the 
reduction of the second (aromatic) carbonyl20. Thus, the role of albumin is to provide a combination of 
chemo- and stereocontrol that can be maintained in the shortened polypeptide only if the overall shape of 
the binding site is substantially conserved. 
Experimental evidence supports the hypothesis that the HSA-catalyzed aldol reaction (Fig. 4 and 5, Table 
2) occurs through an enamine intermediate via a mechanism similar to that of type 1 aldolases. Lysine 199 
reacts with acetone to produce the acetone enamine, which acts as nucleophile toward the aldehyde 
substrate. The conservation of aldolase activity in the peptide suggests that the peculiar pK of the key 
lysine residue is not significantly altered in the shortened protein sequence, indicating a conserved local 
environment. These data demonstrate the possibility of successfully obtaining aldolase peptides with 
enhanced efficiency and stereoselectivity from mutated libraries of GST-HSA100. 
In summary, GST-HSA100 scaffolds can be used in both engineering and display screening technologies and 
have the potential to overcome the limitations of conventional recombinant antibodies as library 
templates.  
 
Methods   
Materials 
 HSA essentially free of fatty acids (A3782), (±)-warfarin (A2250) and all other reagents were purchased 
from Sigma–Aldrich. SPR reagents, buffers and the research-grade Sensor Chip CM5 were obtained from GE 
Healthcare Bio-Sciences. Efavirenz was synthesized as previously reported41. Phosphate buffer (10 mM 
Na2PO4, 1.76 mM KH2PO4, pH 7.4) was used to perform all CD and fluorescence experiments. PBS was used 
in SPR analyses. 
Cloning of the HSA binding site II 
The HSA binding site II domain sequence was designed with a codon optimization strategy for E. coli 
expression and ordered from Invitrogen GeneArt. The optimized sequence was subcloned from the original 
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pMA vector into the prokaryotic expression vector pGEX 4T-1 (GE Healthcare) to yield GST fusion products. 
All cloning was verified by sequencing. 
GST-HSA100 production and purification  
Positive colonies harboring the GST construct were grown, and GST-HSA100 was expressed and purified as 
previously reported 42. Briefly, cells were grown to an OD of 0.6 at 600 nm and induced overnight with 0.2 
mM IPTG at 20°-25°C. Bacteria were harvested by centrifugation, and the cell pellets were lysed with 10 
ml of lysis solution for each gram of bacteria, containing lysis buffer (20 mM Tris pH 8.00, 500 mM NaCl, 
0.1% Triton X-100), 400 µg/mL lysozyme, 50 µg/mL DNase, and a protease inhibitor cocktail. After 
centrifugation, the supernatants were collected and purified by affinity chromatography using Glutathione 
Sepharose 4B (GE Healthcare) according to the manufacturer’s instructions. Fractions were subsequently 
pooled and dialyzed in phosphate buffer or PBS overnight at 4°C. Protein production and purity was 
verified by SDS-PAGE followed by Coomassie Blue staining and Western blotting using anti-FLAG antibody. 
CD spectroscopy 
CD spectra were obtained on a Jasco J-710 spectropolarimeter. Spectra were recorded in a 0.2-cm quartz 
cuvette at temperatures ranging from 5 to 75°C. Data were collected with a data pitch of 0.2 nm, a 
scanning speed of 50 nm/min and a bandwidth of 1 nm. Each spectrum was the average of 10 scans. A 
1.35 μM stock solution of GST-HSA100 was prepared and diluted to 135 nM for CD measurements. 
Fluorescence 
Warfarin and efavirenz stock solutions were prepared in acetonitrile. Steady-state fluorescence spectra 
were acquired at 298 K on a CARY Eclipse (Varian) spectrofluorimeter. Synchronous fluorescence spectra 
were measured in the 240-320 nm excitation range, and the emission was recorded at Δ = 60 nm. The 
concentration of protein (HSA, GST, or GST-HSA100) was maintained at 1 μM in 350 μl phosphate buffer, 
whereas the concentration of warfarin or efavirenz was gradually increased (from 1 to 300 μM and 1 to 2 
mM for warfarin and efavirenz, respectively). After the addition of each ligand, the fluorescence intensity 
at the maximum emission wavelength and the drift of such maximums were measured after equilibrium 
had been reached (15 min). 
SPR analysis 
The efavirenz derivative 2b was dissolved at a 1 mM concentration in 1:10 borate buffer (10 mM disodium 
tetraborate, 1 M NaCl) with 5% of DMSO. Derivative 2b was then coupled to Sensor chip CM5 using an 
EDC/NHS coupling kit in 1:10 HBS-EP buffer [0.1 M HEPES, 1.5 M NaCl, 30 mM EDTA, 0.5% v/v p20 
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surfactant] Excess active esters were deactivated with ethanolamine. The coupling reactions were 
performed using a flow rate of 10 μl/min for 7 min, resulting in densities that were approximately 400± 50 
RU on average. Analyses of interactions were carried out with a constant flow rate of 10 μL/min in PBS (53 
mM Na2HPO4.7H20, 12.5 mM KH2PO4, 70 mM NaCl, pH 7.4) as running buffer with an optimal GST-HSA100 
concentration of 5 μM. After each cycle, both surfaces were regenerated with 30% acetonitrile in 1 mM 
NaOH. The reference data from a deactivated flow cell were subtracted from the sensorgrams, and the 
interaction equilibrium constant was calculated using the BIACORE X100 evaluation software. 
HPLC 
 Analyses of the reduction of diketone 3 and the aldol addition of acetone to aldehyde 5 were performed 
on a HP1100 series instrument equipped with a C18 Phenomenex Luna column (5 μm, 150 x 4.60 mm) using 
appropriate mixtures of acetonitrile and water as eluent. A flow rate of 0.5 ml/min was used, and the 
reaction products were monitored at 214 nm. Diketone 3 and its anti and syn diols 4 were separated using 
a 68:32 water/acetonitrile mixture. Aldehyde 5 and its aldol product 6 were separated using a 40:60 
water/acetonitrile mixture.  
Reduction of diketone 3 
 A solution (0.5 ml) of diketone 3 (43 μM) in acetonitrile was added to 0.5 ml of 43 μM GST-HSA100 in 
water, and the resulting mixture was maintained at room temperature for 30 min. A solution (0.5 ml) of 
NaBH4 (75 μM) in water was then added at 20°C, and the resulting mixture was stirred at the same 
temperature for 2 h. The mixture was acidified with trifluoroacetic acid (150 μl), and 1 ml ethanol was 
added. Next, the mixture was filtered with a 0.22-μm filter and analyzed by HPLC.  
Aldol reaction 
 GST-HSA100 (200 μM) in 90 μl of phosphate buffer (0.05 M Na2HPO4, 0.5 M NaCl, pH 7.5) was incubated at 
37°C for 15 min. A solution of aldehyde 5 (2 μl) in acetonitrile was added for final concentrations ranging 
from 0.5 to 2 mM followed by the addition of 10 μl of acetone. The samples were subsequently sealed and 
kept at 37°C. Initial velocities of the aldol reaction were obtained by measuring the concentrations of 
aldehyde and aldol products by HPLC, while the reactions went to 5% completion. 
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Figure Legends 
 
 
Figure 1. Structure of the human serum albumin HSA-100 fragment  
(a) The full-length protein and HSA-100 fragment are shown as white and red ribbons, respectively. The 
structure was obtained from the Protein Data Bank (1BKE). (b) Designed construct bearing the polypeptide 
GST-HSA100. (c) SDS-PAGE and anti-FLAG tag Western blot of purified GST-HSA100 protein. (d) Tryptic 
map of GST-HSA100. Tryptic peptides obtained by GST-HSA100 digestion were analyzed by LC-MS/MS. Only 
peptides covering the GST-HSA100 sequence are shown. Their identities were assigned on the basis of 
molecular mass (red bars) or peptide sequence (blue bars).  
 
Figure 2. Circular dichroism of GST-HSA100 
(a) Far-UV CD spectra. Solid line, 25°C; dashed line, 60°C; dotted line, 75°C. The spectra were recorded 
at 0.2 μM protein in 10 mM phosphate buffer, pH 7.4. (b) Near-UV CD spectrum of GST-HSA100. 
 
 
Figure 3. GST-HSA100 small ligand binding 
(a) Reference albumin IIa site ligands. (b) Synchronous (Δ=60 nm) fluorescence spectra of GST-HSA100 1 
μM in 10 mM phosphate buffer, pH 7.4. 1, no quencher added; 2, 10 μM efavirenz; 3, 100 μM efavirenz; 4, 
200 μM efavirenz; and 1-4, difference between spectrum 1 and 4. (c) Titration of fluorescence emission of 
HSA, GST-HSA100 and GST by warfarin and efavirenz. ●, warfarin-HSA; ▲, warfarin-HSA100; ■, warfarin-
GST; ○, efavirenz-HSA; ∆, efavirenz-HSA100; □, efavirenz-GST. 
 
 
Figure 4. Control of reactivity with GST-HSA100 
(a) Diastereoselective reduction of 1,3-diketones. (b) Albumin-catalyzed aldol addition. 
 
 
Figure 5.Aldolase activity of GST-HSA100 
Michaelis–Menten plot of the initial velocities for the aldol addition of acetone to aldehyde 5 catalyzed by 
HSA (●) and GST-HSA100 (○). 
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Tables   
 
 
Table 1. Binding parameters for warfarin and efavirenz 
 Warfarin Efavirenz 
 HSA HSA100 HSA HSA100 
KSV[a] 
Lmol-1 
24350 23870 5750 4310 
kq[b] 
Lmol-1s-1 
4.87x1012 4.77x1012 1.15x1012 8.62x1011 
KD[c] 
molL-1 
2.47x10-6 2.70x10-6 1.89x10-4 2.61x10-4 
n[d] 1.07 1.02 0.98 0.98 
Kass[e] 
Lmol-1 
  7.1x103 5.9x103 
[a] Stern-Volmer quenching association constant. [b] Bimolecular quenching 
kinetic constant, assuming τ0=5ns for the tryptophan fluorescence decay. [c] 
Dissociation constant for the protein-ligand complexes from Hill analysis of the 
quenching data. [d] number of binding sites per molecule of protein from Hill 
analysis of the quenching data. [e] SPR steady state association equilibrium 
constant. 
 
 
Table 1  
 
 
 
Table 2: control of reactivity 
Protein Diastereoselective reduction of 
diketone 3 
Kinetic parameters (at 37°C) for the uncatalyzed, HSA and GST-HSA100-catalyzed aldol 
addition of acetone to aldehyde 5
 %anti %syn kunc[a] kcat[b] 
kcat/kunc KM[b] kcat/KMkunc 
   103 min-1 103 min-1  10-3 molL-1 Lmol-1 
BSA 98 2      
HSA 88 12 0.00804 10.0 1244 2.1 5.9x105 
GST-HSA100 90 10 0.00804 9.4 1170 3.0 3.9x105 
[a] observed pseudo first order value. [b] apparent value in 10% aqueous acetone.  
 
Table 2   
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SUPPLEMENTARY INFORMATIONS 
 
Supplementary figure 1. Synchronous (Δ=60 nm) fluorescence spectra of GST-HSA100 1 μM in 10 mM 
phosphate buffer, pH 7.4. 1, no quencher added; 2, 60 μM warfarin; 3, 100 μM warfarin; 4, 200 μM 
warfarin. 
 
 
Supplementary figure 2. SPR sensogram for binding of  GST-HSA100 to an efavirenz-coated surface.  
  
 
Supplementary figure 3: fluorescence-quenching titration in a 384-microwell plate format using a 
fluorimetric plate reader equipped with 280±15 nm excitation and 350±15 nm emission filters to detect 
tryptophan fluorescence. GST-HSA100 was 20 μM. 
 
 
Table 1: GST-HSA100 peptides detected by mass spectrometry 
Peptide 
Molecular Mass Elution 
(min) m/z
1+ m/z2+ m/z3+ sequenced (MS/MS) 
th. exp. 
196-197 302.17 302.2 3.8 303.2    
200-205 648.32 648.5 11.4 649.3 325.2   
206-209 507.24 507.3 8.5 508.3    
200-209 1137.56 1137.6 19.7 1138.5 569.8 380.2 X 
210-212 364.21 364.2 5.1 365.2    
213-218 672.37 672.4 19.9 673.4 337.2  X 
219-222 502.28 502.3 4.5 503.3    
223-225 390.22 390.2 10.6 391.2    
226-233 879.43 879.4 19.4 880.4 440.7  X 
234-240 788.46 788.5 20.2 789.5 395.3  X 
258-262 516.29 516.3 5.9 517.3    
263-274 1385.61 1385.6 20.2  693.8  X 
 
Supplementary table 1   GST-HSA100 LC-MS/MS identification. 
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